Johnson & Johnson’s 2026 Oncology Care Index Finds Community Oncologists Confident in AI’s Promise, but Practical Adoption Still Lags

HORSHAM, PA, September 14, 2026 - Johnson & Johnson (NYSE: JNJ) today released findings from its 2026 Oncology Care Index, a comprehensive survey conducted in partnership with The Harris Poll to look at the state of cancer delivery in the U.S. This year, the Index surveyed 200+ community oncologists and practice administrators across the United States and revealed a striking paradox in community oncology: AI use is accelerating and confidence in AI among oncologists is high, but advanced implementation remains limited. Just over 8 in 10 community oncologists surveyed (83%) believe AI can help make cancer care more accessible for more patients, yet only 19% are currently using AI-powered predictive models. The barrier is not a lack of awareness or openness, but a lack of the tools, training and infrastructure needed to use AI confidently and consistently in practice.¹

Community oncology practices form the backbone of cancer care, caring for nearly 85 percent of people living with cancer in the U.S.² Johnson & Johnson is sharing these findings to identify where implementation challenges persist and what it will take to help community practices translate innovation into meaningful patient impact.

The survey revealed three key themes about AI implementation in community oncology:

• Adoption must move from early use to sustained impact. Nearly half of community oncologists surveyed reported actively using AI tools - 49%, up from 19% of healthcare providers in all practice settings in 2025.
• Familiarity and confidence are high, but usage lags. More than three-quarters of surveyed community oncologists are familiar with AI-powered predictive models and feel confident in their ability to use AI to inform treatment decisions (79%), yet 19% are currently using these tools.
• Practical enablement is now the priority. Most community oncologists say more education and advocacy are needed to accelerate AI adoption. But the real barriers are structural: lack of reimbursement for AI-powered tools (44%), limited formal training (43%) and insufficient funding (41%).

"The Oncology Care Index shows that community oncologists are not waiting to be invited to the AI conversation. We are already in it, but what we need now are the tools, the training, and the structural support to move from early experimentation to consistent, confident practice," said Dr. Stephen (Fred) Divers, Chief Medical Officer at American Oncology Network. "These findings give us the evidence base to make that case to payers, policymakers, and health systems, so that patients in the smallest communities can benefit from the same innovations as those in large cities or academic centers."

Community practices are ready to lead: 78% of surveyed community oncologists, and 96% of surveyed administrators say community oncology practices are uniquely positioned to accelerate access to new cancer treatments. But payer barriers remain a real obstacle: 97% say they delay or prevent patients from receiving the therapies they believe are most appropriate.

Three opportunity areas emerged where targeted action can help turn readiness into impact:

1. Helping to solve cancer research's participation problem: 60% of community oncologists surveyed say their practice offers limited trial options. Reimagining trials around real-world patient education, an approach 94% say would boost participation, can make research more accessible where patients already receive care.
2. Scaling AI's early momentum: AI-adopting practices report greater confidence in their ability to expand care and lead their communities forward. Investing in training, reimbursement pathways and implementation support now will determine whether AI's early momentum becomes lasting impact.
3. Closing the immunotherapies confidence gap: More than 9 in 10 community oncologists surveyed feel their practice is comfortable managing (92%) and is equipped to offer (94%) new immunotherapies, but fewer are very comfortable (43%) or very equipped (35%). Staff training and expertise to implement immunotherapies; financial and reimbursement resources; and infrastructure to develop adverse event management protocols were the top-cited barrier (38%; 38%; 37% respectively).

"Last year, the Oncology Care Index established a baseline. Year two tells us something more urgent: the gap between what community oncologists believe AI can do and what they can actually do with it today isn't closing on its own," said Kevin Hamill, Company Group Chairman, Johnson & Johnson Innovative Medicine North America. "That's not a confidence problem: it's a systems problem, which is why we're investing directly in areas that can help move them from readiness to real impact."

To accelerate progress on these priorities, J&J is issuing a request for proposal designed to support not for profit organizations working in cancer care to implement solutions that address the key barriers identified in the 2026 Oncology Care Index.

J&J is also advancing other solutions to help community settings, including Medical Affairs Implementation Science Grants supporting clinical trial infrastructure, developing programs that scale pathways for delivering advanced immunotherapies closer to home, and collaborating with NCODA (Network for Collaborative Oncology Development and Advancement) through Project Community to identify and overcome key care gaps to raise quality of and access to innovation. In addition, J&J is supporting AI upskilling of the U.S. rural health workforce in a coordinated investment with Google.org.

Learn more about the Oncology Care Index and how J&J is driving change at:
https://www.jnj.com/innovativemedicine/oncologycareindex.
____________________

Johnson & Johnson's Oncology Care Index Survey Methodology
Johnson & Johnson's Oncology Care Index is a survey that asked healthcare professionals working in oncology to identify the challenges they face in delivering the best care for their patients. The research was conducted online in the United States by The Harris Poll on behalf of Johnson & Johnson among:

• 109 community oncologists age 18+ who are duly licensed, and whose primary medical specialty was in hematology/oncology and have treated patients with solid tumor and hematologic cancer in a community setting.
• 100 practice administrators/managers age 18+ employed in healthcare at a practice specializing in hematology/oncology in a community setting that treats hematologic and solid tumor cancer.

The survey was conducted May 21-July 6, 2026. Healthcare professionals and physicians who qualified for and successfully completed the survey were compensated for their participation.

Raw data are not weighted and therefore only representative of the individuals who completed the survey. Respondents for this survey were selected from among those who have agreed to participate in our surveys.

The sampling precision of Harris online polls is measured by using a Bayesian credible interval. For this study, the sample data are accurate to within ± 9.6 percentage (for practice administrators and managers) and within ± 9.3 percentage (for community oncologists) points using a 95% confidence level. This credible interval will be wider among subsets of the surveyed population of interest.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at https://www.jnj.com/innovativemedicine/. Follow us at @JanssenUS and @JNJInnovMed. Janssen Research & Development, LLC, and Janssen Biotech, Inc., are both Johnson & Johnson companies.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, https://investor.jnj.com, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Source: Johnson & Johnson

Footnotes
"Dr. Stephen (Fred) Divers has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work."
¹Johnson & Johnson & The Harris Poll. (2026)
²Association of Cancer Care Centers. ACCC Community Oncology Research Institute. Available at: https://www.accc-cancer.org/education and-resources/research/accc-community-oncology-research-institute.

Media contact:
Eliza Oristano
[email protected]

Investor contact:
Jessica Margavich
[email protected]